Company news
Racura Oncology Ltd (ASX:RAC) news
Racura Oncology Ltd news releases on 6ix. Latest, Aug 31, 2026: CPACS Trial Opens for RC220 Patient Enrolment in Korea
Press releases & updates
CPACS Trial Opens for RC220 Patient Enrolment in Korea
August 31, 2026
First HARNESS-1 Patient Safely Treated with RC220
July 28, 2026
June 2026 Quarterly Activities Report and Appendix 4C
July 27, 2026
Bellberry Ethics Approval Activates New HARNESS Trial Sites
July 2, 2026
Racura Oncology Doses First Patient in Phase 1 HARNESS-1 Trial of RC220 in EGFR-Mutant Non-Small Cell Lung Cancer
June 25, 2026
Racura Treats First Patient in HARNESS-1 Lung Cancer Trial
June 24, 2026
Racura raised $34.3m to Advance Three Oncology Trials
June 15, 2026
Emerging Companies Specialist Invests in Racura
June 3, 2026
Racura Enters Underwriting Agreement for Options
May 28, 2026
Racura Oncology Announces Positive Safety Review Committee Recommendation in ongoing CPACS Clinical Trial
May 15, 2026
CPACS Trial Cleared to Escalate to Next RC220 Dose Level
May 14, 2026
(E,E)-bisantrene Discovered to Function via Silencing of c-MYC Expression
May 6, 2026
March 2026 Quarterly Activity Report and Appendix 4C
April 29, 2026
Racura presents MYC silencing data at AACR 2026
April 22, 2026
First Patient Recruited to HARNESS-1 Lung Cancer Trial
March 31, 2026
First Patient Dosed Safely with RC220 in Hong Kong
March 18, 2026
Racura HARNESS-1 Trial Receives Governance Approval
March 15, 2026
Appendix 4D & Half-Year Financial Statements
February 27, 2026
Racura Develops Novel Cardioprotection Blood Test
February 10, 2026
December 2025 Quarterly Activity Report and Appendix 4C
January 28, 2026
Racura Oncology Emory University Collaboration
January 13, 2026
Racura Oncology Appoints BDD for HARNESS-1 Trial
December 23, 2025
Race Oncology Completes $3.22m Private Placement
December 8, 2025
Race Receives $2.8m RD Tax Refund
November 26, 2025
HARNESS1 Lung Cancer Trial Receives Human Ethics Approval
November 25, 2025
Race Clinical Program Update
November 16, 2025
September 2025 Quarterly Activity Report and Appendix 4C
October 30, 2025
Race Presents Mechanism of Action Data at ESMO 2025
October 19, 2025
Discovery of the Anticancer Mechanism of (EE)-bisantrene
October 1, 2025
RC220 IND Approval from Korean MFDS
September 23, 2025
Race Breakthrough Composition of Matter IP Discovery
September 15, 2025
First Hong Kong Site Activated for RC220 Trial
September 1, 2025
Appendix 4E & Annual Report
August 26, 2025
June 2025 Quarterly Activity Report and Appendix 4C
July 22, 2025
RC220 Human Ethics Approvals Received in Hong Kong
July 9, 2025
First Patient Safely Combine Dosed in Phase 1 RC220 Trial
June 18, 2025
First Patient Dosed Safely in RC220 Phase 1 Trial
April 30, 2025
March 2025 Quarterly Activity Report and Appendix 4C
April 22, 2025
Enrolment Opened at Second Site for RC220 Phase 1 Trial
April 21, 2025
RC220 Phase 1 Trial Opens for Patient Enrolment
April 2, 2025
Race Initiates First AU Site for Phase 1 Solid Tumour Trial
March 27, 2025
Ethics approval received for RC220 Phase 1 Trial
March 13, 2025
S&P DJI Announces March 2025 Quarterly Rebalance
March 7, 2025
Race Signs Contract for Phase 1 Trial of RC220
March 4, 2025
Quarterly Activity Report and Appendix 4C
January 30, 2025
Race Receives $5.25m RD Tax Refund for Financial Year 2024
December 16, 2024
Race Submits Human Ethics for RC220 Phase 1 Trial
December 4, 2024
Race Discovers Multiple Novel FTO Inhibitor Candidates
November 20, 2024
Race Oncology Board Renewal Update
September 1, 2024
Bisantrene Phase 2 AML Trial Successful Concludes
July 29, 2024